期刊
NANO LETTERS
卷 21, 期 9, 页码 3965-3973出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.nanolett.1c00648
关键词
nanovaccine; self-assembly; synergistic immune response; cancer immunotherapy
类别
资金
- Natural Science Foundation of China [31870920]
- CAMS Innovation Fund for Health and Longevity pilot project (Youth Award Program) [2019-RC-HL-015]
- Hundred-Talent Program of Chinese Academy of Sciences [CAMS-I2M-3-004]
- CAMS Innovation Fund for Medical Sciences [CAMS-I2M-3-004]
Nanovaccines incorporating two adjuvants and antigens were efficiently constructed, overcoming obstacles in traditional vaccine preparation and enhancing immune responses. The selected adjuvants achieved a notable immune response through synergistic activation of signaling pathways, significantly inhibiting tumor growth and prolonging the survival time of mice.
Nanovaccines have emerged as promising agents for cancer immunotherapy. However, insufficient antitumor immunity caused by inefficient antigen/adjuvant loading and complicated preparation processes are the major obstacles that limit their clinical application. Herein, two adjuvants, monophosphatidyl A (MPLA) and CpG ODN, with antigens were designed into a nanovaccine to overcome the above obstacles. This nanovaccine was constructed with adjuvants (without additional materials) through facile self-assembly, which not only ensured a high loading efficacy and desirable safety but also facilitated clinical translation for convenient fabrication. More importantly, the selected adjuvants could achieve a notable immune response through synergistic activation of Toll-like receptor 4 (TLR4) and TLR9 signaling pathways, and the resulting nanovaccine remarkably inhibited the tumor growth and prolonged the survival of tumor-implanted mice. This nanovaccine system provides an effective strategy to construct vaccines for cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据